TechOne Biosciences and Institut Curie secure €3.3 million for breast cancer diagnostic development
Pulse2 reports that France 2030’s i-Démo program is funding work on an AI-powered, single-cell diagnostic intended to guide treatment decisions in triple-negative breast cancer.
TLDR
Pulse2 reports that One Biosciences and Institut Curie secured €3.3 million through France 2030’s i-Démo program. The funding is intended to accelerate development of what they aim to commercialize as the first single-cell diagnostic platform for guiding treatment decisions in triple-negative breast cancer.
Combined views
17
1 Source, first seen 4h ago
One Biosciences and Institut Curie secure €3.3 million for breast cancer diagnostic development
Pulse2 reports that France 2030’s i-Démo program is funding work on an AI-powered, single-cell diagnostic intended to guide treatment decisions in triple-negative breast cancer.
TLDR
Pulse2 reports that One Biosciences and Institut Curie secured €3.3 million through France 2030’s i-Démo program. The funding is intended to accelerate development of what they aim to commercialize as the first single-cell diagnostic platform for guiding treatment decisions in triple-negative breast cancer.